Related references
Note: Only part of the references are listed.PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120
Grazia Fazio et al.
EBIOMEDICINE (2022)
Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study
Naomi Michels et al.
Lancet Haematology (2021)
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols
Gunnar Cario et al.
HAEMATOLOGICA (2020)
The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia
Parveen Shiraz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome
Anouchka P. Laurent et al.
LEUKEMIA (2020)
Integrated genetic and epigenetic analysis revealed heterogeneity of acute lymphoblastic leukemia in Down syndrome
Yasuo Kubota et al.
CANCER SCIENCE (2019)
Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group
Kathryn G. Roberts et al.
BLOOD (2018)
IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
Martin Stanulla et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Digital Multiplex Ligation-Dependent Probe Amplification for Detection of Key Copy Number Alterations in T- and B-Cell Lymphoblastic Leukemia
Anne Benard-Slagter et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
A. M. Savino et al.
LEUKEMIA (2017)
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome
Omer Schwartzman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia
Elena Vendramini et al.
ONCOTARGET (2017)
Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant
Jennifer Richmond et al.
CANCER RESEARCH (2016)
Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers
Babak Alaei-Mahabadi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia
Chiara Palmi et al.
ONCOTARGET (2016)
Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia
Cristina Bugarin et al.
HAEMATOLOGICA (2015)
Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia
Cristina Bugarin et al.
HAEMATOLOGICA (2015)
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group
Trudy D. Buitenkamp et al.
BLOOD (2014)
Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations
Sergey I. Nikolaev et al.
NATURE COMMUNICATIONS (2014)
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
Bhagwan Yadav et al.
SCIENTIFIC REPORTS (2014)
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Kathryn G. Roberts et al.
CANCER CELL (2012)
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia
C. Palmi et al.
LEUKEMIA (2012)
Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations
T. D. Buitenkamp et al.
LEUKEMIA (2012)
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Martin Schrappe et al.
BLOOD (2011)
TEL/AML1-Positive Patients Lacking TEL Exon 5 Resemble Canonical TEL/AML1 Cases
Marketa Zaliova et al.
PEDIATRIC BLOOD & CANCER (2011)
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
Libi Hertzberg et al.
BLOOD (2010)
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter et al.
BLOOD (2010)
Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group
Torsten Haferlach et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome
Ken I. Mills et al.
BLOOD (2009)
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia
Charles G. Mullighan et al.
NATURE GENETICS (2009)
Global approach to the diagnosis of leukemia using gene expression profiling
T Haferlach et al.
BLOOD (2005)
Share Paper
